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Abstract 
B Cell Maturation Antigen (BCMA) is a 
transmembrane signaling protein preferentially 
expressed on plasma cells. Its ligands include B-
Cell Activating Factor (BAFF) and A Proliferation 
Inducing Ligand (APRIL). BCMA is involved in 
JNK and NF-kB activation pathways that induce B-
cell development and autoimmune responses. 
BCMA has been implicated in autoimmune 
disorders as well as B-lymphocyte malignancies. 
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Identity 
Other names: BCM, BCMA, CD269, 
TNFRSF13A 
HGNC (Hugo): TNFRSF17 
Location: 16p13.13 
DNA/RNA 
Description 
Spans 3.8 kb; 3 exons, 2 introns. 
Transcription 
961 nt mRNA. 
Protein 
Description 
184 aa; a glycoprotein with a single transmembrane 
domain; N-terminally glycosylated at asparagine 42 
regulates its function (Huang et al., 2013).  
BCMA is a signaling protein that activates the NF-
kB.  
BCMA contains one cysteine rich domain and a 
DXL motif, comprised of (Phe/Tyr/Trp)-Asp-Xaa-
Leu-(Val/Thr)-(Arg/Gly), to facilitate ligand 
binding with BAFF or APRIL (Hymowitz et al., 
2005). 
Expression 
Preferentially expressed in lymph node tissue, B 
lymphoblast, NK cells, and dendritic cells. 
Localisation 
Plasma membrane. 
Function 
BCMA mediates the development and survival of B 
cell lymphocytes that maintain humoral immunity. 
Homology 
TNFRSF17 is conserved in P. Troglodytes, M. 
mulatta, C. lupus, B. taurus, M. musculus, and R. 
norvegicus. 
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Mutations 
22 single nucleotide polymorphisms (SNP) have 
been reported. 
Implicated in 
Multiple myeloma 
Disease 
Multiple myeloma is a fatal malignancy that 
involves the abnormal proliferation and 
accumulation of plasma cells characterized by their 
resistance to apoptosis. Sanchez et al. not only 
showed increased expression of BCMA in patients' 
plasma cells, but that patients with multiple 
myeloma have a high concentration of BCMA 
protein circulating in their blood. Furthermore, the 
group found that higher levels of circulating BCMA 
are associated with a worse prognosis. 
Prognosis 
Poor. 
Acute myelomonocytic leukemia 
(AMML) with eosinophilia 
Disease 
AMML is a malignancy involving myeloid 
precursors of the bone marrow. Although this 
condition is rare, it is a common type of pediatric 
acute myeloid leukemia. In about 50% of the cases 
of AMML, increased numbers of abnormal 
eosinophils are observed in the bone marrow 
(eosinophilia). AMML patients with eosinophilia 
who carry a pericentric inversion at 16(p13q22) 
tend to have a better prognosis. 
Prognosis 
61% 5 year survival rate; AMML patients who 
carry the pericentric inversion have a higher rate of 
complete remission than those without the inversion 
(Chang et al., 2006). 
Cytogenetics 
Pericentric inversion at 16(p13q22) in 3-5% of 
AMML cases. 
T cell lymphoma 
Note 
(4;16)(q26;p13.1) chromosome translocation, 
which led to the discovery of BCMA, was noted by 
Laâbi et al. in a single case of T cell lymphoma. 
This translocation resulted in a IL-2/BCMA 
composite gene. 
 
Partial R-Banded karyotype. The karyotype shows a 
(4;16) (q26;p13.1) chromosomal translocation that led to 
the identification of BCMA by Laâbi et al. (Laâbi et al., 
1992). 
Acute monocytic leukemia 
t(8;16)(p11;p13) translocation has been noted in 
cases of acute monocytic leukemia (Laâbi et al., 
1992). 
Follicular lymphoma 
Translocation (16;18)(p13;q21.3) has been reported 
in follicular lymphoma (Mahmoodi et al., 2004). 
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